Streetbeat News

Price Targets

HWC

DA Davidson analyst Gary Tenner maintains a Buy rating on Hancock Whitney (NASDAQ:HWC) and raises the price target from $55 to $57.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 2:10 pm

COIN

Compass Point analyst Joe Flynn maintains a Buy rating on Coinbase Global (NASDAQ:COIN) and raises the price target from $235 to $325.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 2:07 pm

NIC

Stephens & Co. analyst Terry McEvoy reiterated an Equal-Weight rating on Nicolet Bankshares (NYSE:NIC) and maintained a $92 price target.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 2:06 pm

HWC

Stephens & Co. analyst Matt Olney reiterated an Equal-Weight rating on Hancock Whitney (NASDAQ:HWC) and maintained a $50 price target.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 2:02 pm

PANW

Analyst ratings for Palo Alto Networks (NASDAQ:PANW) show a diverse range of perspectives, with 31 analysts offering their views in the last three months. The sentiment has slightly shifted towards more bullish, with an increase in the average 12-month price target to $353.68 from $350.60. Analyst actions include both upgrades and downgrades, reflecting responses to market conditions and company performance. Palo Alto Networks is highlighted for its strong financial health, including a notable revenue growth rate of 19.33%, an impressive net margin of 88.45%, and an ROE of 53.52%, indicating strong profitability and effective cost control.

Portfolio Pulse from Benzinga Insights

April 17, 2024 | 2:01 pm

LEGN

Analyst ratings for Legend Biotech (NASDAQ:LEGN) show a diverse range of opinions, with recent updates indicating a shift towards more bullish sentiments. The average 12-month price target for LEGN has been raised to $84.25, marking an 8.01% increase from the previous target of $78.00. Legend Biotech, a clinical-stage biopharmaceutical company, has shown significant revenue growth of 187.57% as of December 31, 2023, outperforming peers in the Health Care sector. However, the company faces challenges with a net margin of -182.24% and below-average ROE and ROA, indicating potential profitability and asset utilization issues.

Portfolio Pulse from Benzinga Insights

April 17, 2024 | 2:01 pm

HWC

In the last three months, 6 analysts have provided diverse ratings on Hancock Whitney (NASDAQ:HWC), with recent assessments showing a shift towards a more cautious outlook. The average 12-month price target for HWC has been adjusted to $50.5, slightly lower than the previous $51.00, reflecting a downward trend in expectations. Analysts from firms including Piper Sandler, Truist Securities, Jefferies, and DA Davidson have updated their ratings and price targets, indicating a nuanced view on the company's future performance. Hancock Whitney's financial health shows challenges in revenue growth, net margin, ROE, and ROA, falling below industry averages, although its debt management appears relatively healthy.

Portfolio Pulse from Benzinga Insights

April 17, 2024 | 2:01 pm

BNTX

BioNTech (NASDAQ:BNTX) received mixed ratings from 11 analysts, with a shift towards bullish sentiment in the last 30 days. The average 12-month price target was raised to $130.82, indicating a positive outlook. Analysts adjusted their ratings and price targets, reflecting recent developments and performance. Despite the optimistic analyst ratings, BioNTech faces economic challenges, including a significant revenue decline and below-average profitability metrics.

Portfolio Pulse from Benzinga Insights

April 17, 2024 | 2:00 pm

TWLO

Analyst ratings for Twilio (NYSE:TWLO) show varied sentiments, with recent evaluations and 12-month price targets indicating a slight increase in the average target to $70.12. The analysis includes actions taken by analysts from firms like Oppenheimer, JMP Securities, and Goldman Sachs, reflecting adjustments in ratings and price targets. Twilio's financial performance is highlighted, showing a revenue growth rate of 5.01% and challenges in net margin and profitability, despite a strong market capitalization and efficient asset management.

Portfolio Pulse from Benzinga Insights

April 17, 2024 | 2:00 pm

LRN

Barrington Research analyst Alexander Paris maintains an Outperform rating on Stride (NYSE:LRN) and keeps the price target at $75.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 1:57 pm